Contact Us
Drug Search Results
More Filters [+]

Burapitant

Alternative Names: burapitant, SSR240600C
Latest Update: 2016-05-26
Latest Update Note: Clinical Trial Update

Product Description

Burapitant (SSR-240,600) is a drug developed by Sanofi-Aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the NK1 receptor. Burapitant inhibited the binding of radioactive substance P to tachykinin NK1 receptors in human lymphoblastic IM9 cells, human astrocytoma U373MG cells, and human brain cortex. (Sourced from: https://drugs.ncats.io/drug/E35SK332MS)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Burapitant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Enuresis|Overactive Bladder|Urinary Incontinence, Urge

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2007-004126-24

P2

Completed

Overactive Bladder|Urinary Incontinence, Urge

2009-02-07

BILADY

P2

Completed

Urinary Incontinence, Urge|Overactive Bladder

2009-02-01

MILADY

P2

Completed

Overactive Bladder|Urinary Incontinence, Urge|Enuresis

2006-05-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions